The Albert Einstein College of Medicine and its affiliates propose to continue to participate in the scientific, educational, and cancer control activities of the Eastern Cooperative Oncology Group (ECOG). This institution, in addition to its unique capability to conduct cancer treatment clinical trials involving laboratory and clinical collaboration, has access to the large numbers of patients required for phase III and combined-modality trials. Investigators from the disciplines of medical oncology, radiation oncology, surgery and gynecologic oncology have and propose to continue to participate in the design, implementation and analysis of ECOG studies at Einstein. In addition, pathologists and immunologists who have collaborated with clinical investigators in the conduct of ECOG trials at this institution propose to continue that collaboration. The institution proposes to continue to provide a group-wide immunoreference laboratory for the Hematology Committee of ECOG. This institution and one of its affiliates (New York Medical College) proposes to continue active participation in the ECOG Bone Marrow Transplant Committee. The State of New York has approved a Certificate of Need for Allogeneic Bone Marrow Transplantation for both Einstein and New York Medical College. It will, therefore, be possible for both institutions to participate in studies of this modality within ECOG. Einstein proposes to increase its accrual to ECOG studies by extending its CGOP network to include additional productive institutions with extensive clinical trials experience and capability.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA014958-18
Application #
3556292
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-06-01
Project End
1994-04-30
Budget Start
1992-05-01
Budget End
1993-04-30
Support Year
18
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Type
Schools of Medicine
DUNS #
009095365
City
Bronx
State
NY
Country
United States
Zip Code
10461
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Erbe, Amy K; Wang, Wei; Goldberg, Jacob et al. (2017) FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res 23:2159-2168
Smith, M R; Hong, F; Li, H et al. (2017) Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia 31:517-519
Schneider, Bryan P; Shen, Fei; Jiang, Guanglong et al. (2017) Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103. JCO Precis Oncol 2017:
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Sanchez-Martin, Marta; Ambesi-Impiombato, Alberto; Qin, Yue et al. (2017) Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proc Natl Acad Sci U S A 114:2006-2011
Roberts, Kathryn G; Gu, Zhaohui; Payne-Turner, Debbie et al. (2017) High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35:394-401
Wang, Wei; Erbe, Amy K; Gallenberger, Mikayla et al. (2016) Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunol Immunother 65:1523-1532
Schneider, Bryan P; Lai, Dongbing; Shen, Fei et al. (2016) Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans. Oncotarget 7:82244-82253
Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel M et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112

Showing the most recent 10 out of 146 publications